JP2009526861A5 - - Google Patents

Claims (17)

A method of preparing a pharmaceutical composition for promoting angiogenesis in an animal comprising an isolated expression vector comprising a polynucleotide selected from: and a pharmaceutically acceptable carrier :
(A) SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9 and SEQ ID NO: 11, and
(B) A sequence encoding a polypeptide having the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10 and SEQ ID NO: 12. An antibody that specifically binds to a polypeptide comprising the amino acid sequence of SEQ ID NO: 10 with high affinity. An antibody that specifically binds with high affinity to the extracellular portion of a polypeptide comprising the amino acid sequence of SEQ ID NO: 4. 4. The antibody of claim 2 or 3 , wherein the antibody is monoclonal. The antibody according to claim 2 or 3 , wherein the antibody is a polyclonal. A method for producing all or part of zebrafish LEC3, CXCR4 or EDNRA,
A host cell comprising an expression vector comprising the sequence of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9 or SEQ ID NO: 11 operably linked to an expression control sequence is transformed into zebrafish LEC3, CXCR4. Or cultured under culture conditions suitable for the expression of all or part of EDNRA,
Isolating all or part of the LEC3, CXCR4 or EDNRA;
A method comprising: A therapeutic composition comprising an isolated polynucleotide comprising a nucleic acid sequence encoding all or part of LEC3, CXCR4 and EDNRA, and a pharmaceutically acceptable carrier. A therapeutic composition comprising the antibody of claim 3 and a pharmaceutically acceptable carrier. A polypeptide comprising at least one amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 10 and SEQ ID NO: 12, and a pharmaceutically acceptable carrier. A therapeutic composition comprising. A method for preparing a pharmaceutical composition for treating angiogenesis-related diseases, comprising a sufficient amount of a polynucleotide to suppress angiogenesis that suppresses LEC3 expression and a pharmaceutically acceptable carrier . An effective amount of a first polynucleotide encoding all or a portion of the LEC 3, CXCR4 and EDNRA polypeptides; an effective amount of a second polynucleotide encoding a VEGF polypeptide; and a pharmaceutically acceptable carrier. A method of preparing a pharmaceutical composition for promoting angiogenesis in an animal in need thereof . A method of identifying a compound that inhibits LEC3, CXCR4 and / or EDNRA activity, wherein the test compound is contacted with LEC3, CXCR4 and / or EDNRA polypeptide, said test compound inhibits LEC3, CXCR4 and / or EDNRA activity A test compound that inhibits the activity of LEC3, CXCR4 and / or EDNRA is identified as an antagonist of LEC3, CXCR4 and / or EDNRA. 13. The method of claim 12 , wherein the biological activity of LEC3, CXCR4 and / or EDNRA is measured by binding the test compound to LEC3, CXCR4 and / or EDNRA. A method for inhibiting angiogenesis, comprising administering to a cell an effective amount of a cell-penetrating peptide that inhibits the biological function of LEC3, CXCR4 and / or EDNRA. 15. The method of claim 14 , further comprising administration of a compound that inhibits VEGF expression or biological function. Methods of preparing the following or et consisting of compounds selected from the group, and a pharmaceutically acceptable carrier, a pharmaceutical composition for promoting angiogenesis:
(A) an isolated expression vector comprising a polynucleotide having the nucleotide sequence of SEQ ID NO: 41, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID NO: 47, SEQ ID NO:
(B) a sequence encoding a polypeptide having the amino acid sequence of SEQ ID NO: 42, SEQ ID NO: 44, SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 50, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 56 and SEQ ID NO: 58; An isolated expression vector comprising a polynucleotide having
(C) A polypeptide comprising the amino acid sequences of SEQ ID NO: 42, SEQ ID NO: 44, SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 50, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 56, and SEQ ID NO: 58. Preparation of a pharmaceutical composition for treating angiogenesis-related diseases comprising an antibody that binds to SDF-1 or ET-1 in an amount sufficient to inhibit angiogenesis and a pharmaceutically acceptable carrier How to do .